NBIX – Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc.NBIX
$143.56Name : Neurocrine Biosciences, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $14,313,749,504.00
EPSttm : 4.19
Neurocrine Biosciences, Inc.
$143.56
0.90%$1.30Float Short %
4.24
Margin Of Safety %
4
Put/Call OI Ratio
1.03
EPS Next Q Diff
-0.18
EPS Last/This Y
3.49
EPS This/Next Y
2.25
Price
143.56
Target Price
174.62
Analyst Recom
1.31
Performance Q
8.09
Relative Volume
0.95
Beta
0.28
Ticker: NBIX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | NBIX | 141.33 | 1.64 | 0.14 | 5963 |
| 2025-10-21 | NBIX | 142.71 | 1.63 | 22.67 | 5967 |
| 2025-10-22 | NBIX | 141.36 | 1.72 | 0.00 | 6170 |
| 2025-10-23 | NBIX | 143.68 | 1.71 | 0.43 | 6185 |
| 2025-10-24 | NBIX | 143.93 | 1.40 | 0.09 | 7257 |
| 2025-10-27 | NBIX | 149 | 1.36 | 0.14 | 7704 |
| 2025-10-28 | NBIX | 147.46 | 1.33 | 0.18 | 7864 |
| 2025-10-29 | NBIX | 137.96 | 1.28 | 0.19 | 8070 |
| 2025-10-30 | NBIX | 137.99 | 0.88 | 0.05 | 10560 |
| 2025-10-31 | NBIX | 143.17 | 0.81 | 0.00 | 11128 |
| 2025-11-03 | NBIX | 141.96 | 0.81 | 0.52 | 11118 |
| 2025-11-04 | NBIX | 143.16 | 0.85 | 0.31 | 11353 |
| 2025-11-05 | NBIX | 153.74 | 0.84 | 0.18 | 11547 |
| 2025-11-06 | NBIX | 154.8 | 0.88 | 0.06 | 11495 |
| 2025-11-07 | NBIX | 152.34 | 0.88 | 0.27 | 11502 |
| 2025-11-10 | NBIX | 149.94 | 0.95 | 2.35 | 11716 |
| 2025-11-11 | NBIX | 147.33 | 0.98 | 2.73 | 11906 |
| 2025-11-12 | NBIX | 146.84 | 0.97 | 2.20 | 11916 |
| 2025-11-13 | NBIX | 144.14 | 0.97 | 0.01 | 11906 |
| 2025-11-14 | NBIX | 144.81 | 1.02 | 0.21 | 11591 |
| 2025-11-17 | NBIX | 143.52 | 1.03 | 0.40 | 11565 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | NBIX | 141.33 | 16.7 | 333.3 | 6.80 |
| 2025-10-21 | NBIX | 142.69 | 16.7 | 334.0 | 6.80 |
| 2025-10-22 | NBIX | 141.47 | 16.7 | 318.1 | 6.80 |
| 2025-10-23 | NBIX | 143.72 | 16.7 | 339.6 | 6.80 |
| 2025-10-24 | NBIX | 144.01 | 14.2 | 327.6 | 6.73 |
| 2025-10-27 | NBIX | 148.92 | 14.2 | 355.8 | 6.73 |
| 2025-10-28 | NBIX | 147.38 | 14.3 | 316.2 | 6.72 |
| 2025-10-29 | NBIX | 137.97 | 14.3 | 268.8 | 6.72 |
| 2025-10-30 | NBIX | 138.04 | 40.3 | 270.5 | 6.71 |
| 2025-10-31 | NBIX | 143.21 | 41.5 | 527.6 | 6.84 |
| 2025-11-03 | NBIX | 141.90 | 41.5 | 474.6 | 6.84 |
| 2025-11-04 | NBIX | 143.18 | 42.7 | 494.6 | 6.89 |
| 2025-11-05 | NBIX | 153.76 | 42.7 | 567.8 | 6.89 |
| 2025-11-06 | NBIX | 154.78 | 42.7 | 492.5 | 6.89 |
| 2025-11-07 | NBIX | 152.37 | 42.7 | 468.0 | 6.89 |
| 2025-11-10 | NBIX | 150.02 | 42.7 | 467.7 | 6.89 |
| 2025-11-11 | NBIX | 147.29 | 42.7 | 464.3 | 6.89 |
| 2025-11-12 | NBIX | 146.80 | 43.7 | 481.4 | 6.90 |
| 2025-11-13 | NBIX | 144.07 | 43.7 | 463.7 | 6.90 |
| 2025-11-14 | NBIX | 144.80 | 42.7 | 490.4 | 6.89 |
| 2025-11-17 | NBIX | 143.56 | 42.7 | 474.7 | 6.89 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | NBIX | -7.77 | 3.44 | 4.42 |
| 2025-10-21 | NBIX | -7.77 | 3.44 | 4.42 |
| 2025-10-22 | NBIX | -7.77 | 3.44 | 4.42 |
| 2025-10-23 | NBIX | -7.77 | 3.44 | 4.42 |
| 2025-10-24 | NBIX | -7.77 | 3.44 | 4.42 |
| 2025-10-27 | NBIX | -7.77 | 2.83 | 4.53 |
| 2025-10-28 | NBIX | -7.77 | 2.83 | 4.53 |
| 2025-10-29 | NBIX | -7.77 | 2.83 | 4.53 |
| 2025-10-30 | NBIX | -7.74 | 2.83 | 4.53 |
| 2025-10-31 | NBIX | -7.74 | 2.83 | 4.50 |
| 2025-11-03 | NBIX | -7.74 | 3.02 | 4.50 |
| 2025-11-04 | NBIX | -7.74 | 3.02 | 4.50 |
| 2025-11-05 | NBIX | -7.75 | 3.02 | 4.50 |
| 2025-11-06 | NBIX | -7.75 | 3.02 | 4.50 |
| 2025-11-07 | NBIX | -8.31 | 3.02 | 4.50 |
| 2025-11-10 | NBIX | -7.37 | 3.13 | 4.50 |
| 2025-11-11 | NBIX | -7.37 | 3.13 | 4.50 |
| 2025-11-12 | NBIX | -7.37 | 3.13 | 4.24 |
| 2025-11-13 | NBIX | -7.37 | 3.13 | 4.24 |
| 2025-11-14 | NBIX | -7.37 | 3.13 | 4.24 |
| 2025-11-17 | NBIX | -7.37 | 5.53 | 4.24 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.17
Avg. EPS Est. Current Quarter
2.41
Avg. EPS Est. Next Quarter
1.99
Insider Transactions
-7.37
Institutional Transactions
5.53
Beta
0.28
Average Sales Estimate Current Quarter
805
Average Sales Estimate Next Quarter
773
Fair Value
149.57
Quality Score
79
Growth Score
99
Sentiment Score
22
Actual DrawDown %
9.1
Max Drawdown 5-Year %
-42.9
Target Price
174.62
P/E
34.28
Forward P/E
20.39
PEG
0.95
P/S
5.34
P/B
4.77
P/Free Cash Flow
24.13
EPS
4.19
Average EPS Est. Cur. Y
6.89
EPS Next Y. (Est.)
9.14
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
15.95
Relative Volume
0.95
Return on Equity vs Sector %
-12.7
Return on Equity vs Industry %
7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.09
EBIT Estimation
474.7
Neurocrine Biosciences, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today
news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance
stock history NBIX – Neurocrine Biosciences, Inc. invest stock market
stock prices NBIX premarket after hours
ticker NBIX fair value insiders trading